Navigation Links
Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services

Boulder, CO (PRWEB) August 01, 2013

Flagship Biosciences, a leading provider of tissue analysis for pharmaceutical and medical device development, has added biostatistics services for preclinical and clinical trials support.

A complete service in tissue analysis requires cancer biologists, pathologists, image analysis experts and biostatisticians all working together. With the addition of biostatistics, Flagship expands its world-class team to fully address a given tissue study, whether early stage biomarker development or clinical trial patient segmentation, or the development of an immunohistochemistry companion diagnostic. Given the changes and fragmentation of outsourcing in the industry today, a team with this set of experts can be a huge value in both time and quality to any drug or device development endeavor, whether a virtual company or a large established pharmaceutical firm.

The pharmaceutical industry and the discipline of pathology are both independently transforming. Large pharmaceutical firms previously relied on in-house pathology and statistical support, and a pathologist and statistician would work together regularly. With downsizing at large pharmaceutical companies and the growth of smaller biotechs and new virtual business models, these two disciplines are frequently now out-sourced. Even with retention of in-house capabilities, the researchers often find they have only limited accessibility to the statisticians, and the iterative process of data interpretation becomes difficult. The essential communication between what the results are by a pathologist and what the results mean by a statistician are frequently disrupted, leading to incomplete analysis of the data.

The discipline of pathology is also undergoing a decade long transition to a digital discipline where quantitation will be expected. “Where previously we relied on a pathologist to give a manual subjective score, there were limits to what a statistician could do with the data, said Dr. Steven Potts, CEO of Flagship Biosciences. “With the newer techniques that Flagship Biosciences is developing, there is a greater need for biostatistics, and also an emerging discipline of pathology statistics. This growth is a natural expansion as the discipline of tissue-based pathology develops towards a more quantitative discipline. Our expansion of in-house biostatistics capabilities will also strengthen our ongoing tissue-based companion diagnostics programs.”

With new approaches to multiple measures of tissue markers which are rich in quantitative data, multivariate statistics becomes central. Even with single-value measurements in immunohistochemistry or immunofluorescence, the correct approach to determining a therapeutic cut-point requires statistics expertise. A statistician must fully understand the process of a pathology study in order to provide advice on critical decisions like sample size, adequate power, outlier analysis, and bias.

Flagship Biosciences is a fast-growing histopathology services firm that works with over one hundred drug and medical device clients and fourteen of the largest fifteen global pharmaceutical companies. Flagship supports discovery and CLIA/GCP clinical trials in quantitative pathology. Flagship’s biostatistics services improve upon their industry-leading digital pathology knowledge and expertise.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
2. BioXcel Launches Its Flagship Product, PharmGPS™
3. Clinovo, Leading CRO in the Bay Area, Endorsed by Medical Device Company for Their Flagship System: Clincapture
4. Neurocrine Biosciences Reports Second Quarter 2013 Results
5. Centrillion Biosciences Announces Winners of Next-gen Sequencing Innovation Grant Program
6. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
7. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
8. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit
9. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
10. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
11. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):